These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 23247492)

  • 1. Efficacy and safety of tumor necrosis factor inhibitors in acute generalized pustular psoriasis.
    Viguier M; Aubin F; Delaporte E; Pagès C; Paul C; Beylot-Barry M; Goujon C; Rybojad M; Bachelez H;
    Arch Dermatol; 2012 Dec; 148(12):1423-5. PubMed ID: 23247492
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment of spondyloarthritides with anti-TNFalpha biologic agents.
    Braun J
    Reumatismo; 2006; 58 Spec No.1():71-2. PubMed ID: 23631067
    [No Abstract]   [Full Text] [Related]  

  • 3. Infliximab-induced psoriasis in treatment of Crohn's disease-associated ankylosing spondylitis: case report and review of 142 cases.
    Famenini S; Wu JJ
    J Drugs Dermatol; 2013 Aug; 12(8):939-43. PubMed ID: 23986169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study.
    Deepak P; Sifuentes H; Sherid M; Stobaugh D; Sadozai Y; Ehrenpreis ED
    Am J Gastroenterol; 2013 Jan; 108(1):99-105. PubMed ID: 23032984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Long-term psoriasis treatment].
    Jullien D; Battistella M
    Ann Dermatol Venereol; 2011 Feb; 138(2 Suppl 1):H15-8. PubMed ID: 21396519
    [No Abstract]   [Full Text] [Related]  

  • 6. Etanercept-induced asthma in a psoriatic patient resolving with transition to ustekinumab.
    Torres T; Vilaça S; Velho G; Selores M
    Eur J Dermatol; 2012; 22(5):696-7. PubMed ID: 22910198
    [No Abstract]   [Full Text] [Related]  

  • 7. Advertisements for TNF Inhibitors.
    Med Lett Drugs Ther; 2008 Nov; 50(1299):89. PubMed ID: 19008788
    [No Abstract]   [Full Text] [Related]  

  • 8. Nodular melanoma arising in a patient treated with anti-tumor necrosis factor alpha antagonists.
    Carlesimo M; La Pietra M; Arcese A; Di Russo PP; Mari E; Gamba A; Orsini D; Camplone G
    Int J Dermatol; 2012 Oct; 51(10):1234-6. PubMed ID: 22416995
    [No Abstract]   [Full Text] [Related]  

  • 9. Treatment of nail psoriasis with tumor necrosis factor-alpha blocker agents: an open-label, unblinded, comparative study.
    Ozmen I; Erbil AH; Koc E; Tunca M
    J Dermatol; 2013 Sep; 40(9):755-6. PubMed ID: 23834032
    [No Abstract]   [Full Text] [Related]  

  • 10. Immunomodulatory therapy with tumour necrosis factor α inhibitors in children with antinuclear antibody-associated chronic anterior uveitis: long-term results.
    Doycheva D; Zierhut M; Blumenstock G; Stuebiger N; Januschowski K; Voykov B; Deuter C
    Br J Ophthalmol; 2014 Apr; 98(4):523-8. PubMed ID: 24457365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RA drugs Enbrel, Humira appear safe.
    Health News; 2005 Mar; 11(3):9. PubMed ID: 15803572
    [No Abstract]   [Full Text] [Related]  

  • 12. Tumor necrosis factor antagonists in the therapy of psoriasis.
    Mössner R; Schön MP; Reich K
    Clin Dermatol; 2008; 26(5):486-502. PubMed ID: 18755367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Infections associated with the use of tumor necrosis factor-α inhibitors in psoriasis.
    Tan X; Balkrishnan R; Feldman SR
    J Drugs Dermatol; 2013 Mar; 12(3):e41-5. PubMed ID: 23545925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Flare and change of psoriasis morphology during the course of treatment with tumour necrosis factor blockers.
    Goiriz R; Daudén E; Pérez-Gala S; Guhl G; García-Díez A
    Clin Exp Dermatol; 2007 Mar; 32(2):176-9. PubMed ID: 17176269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pustular psoriasis following treatment of rheumatoid arthritis with TNF-alpha inhibitors.
    Egnatios G; Warthan MM; Pariser R; Hood AF
    J Drugs Dermatol; 2008 Oct; 7(10):975-7. PubMed ID: 19112764
    [No Abstract]   [Full Text] [Related]  

  • 16. Is there a benefit from using a subsequent anti-TNF α medication in psoriasis patients who failed their first or second anti-TNF α agent?
    Alsharqi A; Parslew R; Dever B; Arslanian V
    Australas J Dermatol; 2012 May; 53(2):e45-7. PubMed ID: 22571585
    [No Abstract]   [Full Text] [Related]  

  • 17. Psoriasis and palmoplantar pustulosis associated with tumor necrosis factor-α inhibitors: the Mayo Clinic experience, 1998 to 2010.
    Shmidt E; Wetter DA; Ferguson SB; Pittelkow MR
    J Am Acad Dermatol; 2012 Nov; 67(5):e179-85. PubMed ID: 21752492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The evolving role of biologics in the treatment of pediatric psoriasis.
    Luu M; Cordoro KM
    Skin Therapy Lett; 2013 Feb; 18(2):1-4. PubMed ID: 23508772
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Switching to adalimumab in patients with moderate to severe psoriasis who have failed on etanercept: a retrospective case cohort study.
    Woolf RT; Smith CH; Robertson K; Barker JN
    Br J Dermatol; 2010 Oct; 163(4):889-92. PubMed ID: 20854408
    [No Abstract]   [Full Text] [Related]  

  • 20. Sacroiliitis in a psoriasis patient after switching from etanercept to ustekinumab.
    Vilaça S; Torres T; Selores M
    Eur J Dermatol; 2013; 23(6):897-8. PubMed ID: 24192318
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.